Gritstone bio (GRTS)
(Real Time Quote from BATS)
$0.83 USD
+0.02 (2.04%)
Updated Apr 29, 2024 03:02 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GRTS 0.83 +0.02(2.04%)
Will GRTS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GRTS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GRTS
Down -63.39% in 4 Weeks, Here's Why Gritstone bio (GRTS) Looks Ripe for a Turnaround
Gritstone (GRTS) Plummets 58% in a Week: Here's Why
GRTS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Do Options Traders Know Something About Gritstone bio (GRTS) Stock We Don't?
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates
Other News for GRTS
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
Gritstone Oncology Announces Board of Directors Changes
Gritstone appoints Stephen Webster to board of directors
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
Gritstone publishes interim results from Phase 1/2 study of SLATE